# A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

> **NCT05394350** · PHASE1,PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 27 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** MK-1088
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05394350
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-07
- **Primary completion:** 2023-09-07
- **Final completion:** 2023-09-07
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394350, "A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05394350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*